Sight Sciences, Inc.

sightsciences.com

What Do They Do?

Sells OMNI and SION surgical devices for glaucoma procedures to ophthalmic surgeons and outpatient surgery facilities. Also sells TearCare devices for dry eye treatment to eye-care professionals.

How Do They Make Money?

Hospitals, medical centers and eye-care professionals buy its devices through sales representatives and distributors. Customers are typically offered 30-day payment terms, and the company is paid when goods transfer to them.

revenue

Segment	Share	Revenue	How money arrives
Interventional Glaucoma Sold outright	98% FY2022: 92%		Sold outright
Interventional Dry Eye Sold outright	2.1% FY2022: 8.0%		Sold outright

Who Are Their Customers?

The company mainly sells directly to outpatient surgery facilities and eye-care professionals through its sales teams. It sells OMNI through distributors in several other European countries.

Do Revenues Turn Into Profits?

No. It lost $38.4M in FY2025.

Operating income, FY2025

−48% of revenue

▼ −27% (Loss) vs FY2024 (−$50.5M, −63%)

Net income, FY2025

−50% of revenue

▼ −25% (Loss) vs FY2024 (−$51.5M, −64%)

Free cash flow, FY2025

−39% of revenue

▲ +32% (Loss) vs FY2024 (−$22.7M, −28%)

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q2 FY2026, the three months to Jun 30, 2026

Revenue: ▲ +20%; vs $19.6M in Q2 FY2025
Net income: ▼ −63% (Loss); vs −$11.9M in Q2 FY2025

Interventional Glaucoma share of revenue vs 98.3% in Q2 FY2025

Aug 5, 2026 Raised 2026 revenue guidance It also lowered its adjusted operating expense guidance.
May 6, 2026 Raised 2026 revenue guidance
Apr 23, 2026 Court awarded damages and royalties in patent case The $55.4 million award and ongoing royalty are subject to appeal by Alcon.

Growing. Revenue grew 58% in 4 years, from $49M in FY2021 to $77.4M in FY2025, about 12% a year.

A narrower standalone glaucoma focus The earlier report described OMNI for adult patients with primary open-angle glaucoma broadly; the latest report focuses standalone procedures on later-stage patients whose pressure remains uncontrolled despite multiple medicines.

Revenue over time

Interventional Glaucoma Interventional Dry Eye

$100M$50M$0

FY2021 FY2022 FY2023 FY2024 FY2025

Who Do They Compete With?

Competes with Glaukos, Alcon, AbbVie, Iantrek, New World Medical, Nova Eye Medical, Johnson & Johnson, and Novartis

Comments